Literature DB >> 12490193

Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines.

Sandra Swiatkowski1, Hans-Helge Seifert, Christine Steinhoff, Andrea Prior, Ingo Thievessen, Freimut Schliess, Wolfgang A Schulz.   

Abstract

It is often assumed that MAPK pathways drive proliferation of normal uroepithelial (UEC) and urothelial carcinoma (TCC) cells. To check this assumption, activities and inducibilities of promoters containing serum-response elements (SRE) or AP-1 binding sites were investigated in cultured UEC and seven TCC lines. Reporter plasmids dependent on SRE or AP-1 sites were highly active in UEC, but significantly less so in TCC lines. Reporter activity in TCC lines could be induced by constitutively active MEKK4 or TPA. Accordingly, phosphorylation of the MAPK pathway components MEK, ERK, and ELK1 was most pronounced in UEC and lower in TCC lines. MAPK-dependent promoter activities and bromodeoxyuridine incorporation decreased in UEC upon withdrawal of growth factors, but less so in TCC lines, in which serum diminution increased apoptosis. Likewise, E2F-dependent promoters responded to growth factors in UEC, but were more serum-independent in the TCC lines, which lack either RB1 or p16(INK4A). MEK inhibitors inhibited BrdU incorporation in UEC more strongly than in TCC lines. Thus, proliferation of normal uroepithelial cells is indeed associated with activation of MAPK pathways. However, autonomous proliferation of TCC lines--unexpectedly--appears much less dependent on MAPK activation and may rather be promoted by defects in cell cycle regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490193     DOI: 10.1006/excr.2002.5647

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  37 in total

1.  Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.

Authors:  Lorena Rosik; Günter Niegisch; Ute Fischer; Manfred Jung; Wolfgang Arthur Schulz; Michèle Janine Hoffmann
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

2.  Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Authors:  Takashi Kawahara; Hiroki Ide; Eiji Kashiwagi; John D Patterson; Satoshi Inoue; Hasanain Khaleel Shareef; Ali Kadhim Aljarah; Yichun Zheng; Alexander S Baras; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

3.  Gene expression profiling of chemically induced rat bladder tumors.

Authors:  Ruisheng Yao; Yijun Yi; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 4.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

5.  [Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?].

Authors:  G Niegisch; A Koch; J Knievel; W A Schulz; P Albers
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

6.  Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation.

Authors:  Jayoung Kim; Susan K Keay; Michael R Freeman
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

7.  Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: A cytology case report and review of the literature.

Authors:  Marilyn M Bui; Chetna N Purohit; Ardeshir Hakam
Journal:  Cytojournal       Date:  2010-09-17       Impact factor: 2.091

8.  Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710.

Authors:  P Nikpour; S J Mowla; S M Jafarnejad; U Fischer; W A Schulz
Journal:  Cell Prolif       Date:  2009-08-25       Impact factor: 6.831

9.  Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine.

Authors:  Ruisheng Yao; William J Lemon; Yian Wang; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

10.  Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.

Authors:  Carolyn Glass; Charles Wuertzer; Xiaohui Cui; Yingtao Bi; Ramana Davuluri; Ying-Yi Xiao; Michael Wilson; Kristina Owens; Yi Zhang; Archibald Perkins
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.